Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02275117 · ClinicalTrials.gov registry record · Phase 2
A Multicenter Assessment of ALD403 in Chronic Migraine
A Phase 2 study, sponsored by Alder Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 665
- Enrollment target
NCT02275117: Completed Phase 2 study, sponsored by Alder Biopharmaceuticals.
NCT02275117 is a Phase 2 study that has completed, run by Alder Biopharmaceuticals. The registered enrollment target is 665 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (400% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02275117, a Phase 2 study, has completed, sponsored by Alder Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 665 participants
- Enrollment target
Study Summary
The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
Primary Outcome
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ALD403
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 665 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
What the finished NCT02275117 record still lists
NCT02275117 is an interventional study that assigns participants to a tested intervention. The registered 665 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (400% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02275117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02275117 about?
NCT02275117 is a clinical study titled "A Multicenter Assessment of ALD403 in Chronic Migraine". The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
What is the current status of trial NCT02275117?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 665 participants. The study started on 2014-10. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02275117?
The interventions under investigation include: Placebo (BIOLOGICAL), ALD403 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02275117?
This trial is sponsored by Alder Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02275117's enrollment target sits among peer trials
665 49th of 2000 higher than 1,952 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
- NCT06981078 · 666 participants · Phase 2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia